Pharmaceuticals

BioNTech

Marburg Germany

New COVID-19 Vaccine production Site

Marburg,

Germany

One of the vaccines that provides particularly good protection against COVID-19 is BNT162b2 from Mainz-based biotech company BioNTech. To scale-up the manufacturing capacity further, BioNTech had just acquired a new production facility from Novartis and needed to rapidly transform the plant into a COVID-19 vaccine facility.

Entire process flow controlled and orchestrated using Siemens products:

Opcenter Execution Pharma MES to orchestrate subsystems and processes, and analyze their quality. Production processes can be optimized and managed automatically
All systems were automated using the SIMATIC PCS 7 process control system.
Other products used include network technology, WLAN access points, communication technology and the TIA Portal engineering framework.

We want to thank Siemens for their excellent collaboration on this project and the huge effort they put in, often exceeding 100 percent.

Valeska Schilling, Head of Production Department, BioNTech Marburg

Project “Lightspeed” to repurpose a vaccines plant in 5 months.
Eliminate paper & integrate automated operations with an MES, delivered in 2.5 months
Rapid assemble a team of 22 engineers
Automatical optimization and management of processes
SIMATIC PCS 7 and TIA portal for control system and engineering framework enable improvements that are Industry 4.0-campatible
Precise measurement of weight for manual stages in mRNA processes ensuring high product quality
Project Engineering, implementation & hyper-care 24/7 by Siemens

Project Lightspeed, Marburg, Germany

Completion 2021

Stepping up the pace in vaccine development and production

BioNTech - Digitized production for personalized medicine

Release Year 2021

“We give the user a valuable time advantage “

ID: 22576